Topic: synucleinopathy

Multimodal imaging in Dementia with Lewy bodies

Dementia with Lewy bodies (DLB) is a synucleinopathy but more than half of patients with DLB also have varying degrees of tau and amyloid-β co-pathology. Identifying and tracking the pathologic heterogeneity of DLB with multi-modal biomarkers is critical for the design of clinical trials that target each pathology early in the disease at a time when prevention or delaying the transition to dementia is possible. Furthermore, longitudinal evaluation of multi-modal biomarkers contributes to our understanding of the type and extent of the pathologic progression and serves to characterize the temporal emergence of the associated phenotypic expression. This talk will focus on the utility of multi-modal imaging in DLB.

Blaming neuromelanin for Parkinson's disease: time-dependent tyrosinase overexpression drives endogenous synucleinopathy in nonhuman primates

Evidence for prodromal neuroinflammation in a rodent model of alpha- synucleinopathy

The role of EEF1A proteins at synapses and in synucleinopathy

Studying mitophagy in neuronal models of alpha-synucleinopathy with the fluorescent MitoRosella reporter